



Entheon Announces Termination of Consulting Agreement with Cybin

VANCOUVER, BC, April 28, 2023 – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“**Entheon**” or the “**Company**”) today announces that Cybin IRL Limited (“**Cybin**”) has delivered notice to the Company to terminate the consulting services agreement (the “**Consulting Agreement**”) entered into between the Company and Cybin that was announced on July 11, 2022 pursuant to which the Company was to provide ongoing support to the Phase 1 N,N-dimethyltryptamine study. Services under the Consulting Agreement have been fully rendered and fees payable by Cybin to the Company were accelerated as a result of the early termination.

About Entheon Biomedical Corp.

Entheon is a biotechnology research and development company interested in treating addiction and substance use disorders.

On Behalf of the Board of Directors,

Timothy Ko, CEO, President and Director

For more information, please contact the Company at:

Entheon Biomedical Corp.

Timothy Ko, CEO

timothy@entheonbiomedical.com

<https://entheonbiomedical.com>